|
1. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020; 12(4):372. doi.10.3390/v12040372 PMid:32230900 PMCid:PMC7232198 2. Chan JF-W, Yuan S, Chu H, Sridhar S, Yuen K-Y. COVID-19 drug discovery and treatment options. Nat Rev Microbiol. 2024; 22(7):391-407. doi.10.1038/s41579-024-01036-y PMid:38622352 3. Mehta OP, Bhandari P, Raut A, Kacimi SEO, Huy NT. Coronavirus disease (COVID-19): comprehensive review of clinical presentation. Front Public Health. 2021; 8:582932. doi.10.3389/fpubh.2020.582932 PMid:33520910 PMCid:PMC7844320 4. Sethi I, Shaikh A, Sethi M, Chohan HK, Younus S, Khan SA, et al. Dosage and utilization of dexamethasone in the management of COVID-19: A critical review. World J Virol. 2024; 13(3):95709. doi.10.5501/wjv.v13.i3.95709 5. Russell L, Uhre KR, Lindgaard ALS, Degn JF, Wetterslev M, Sivapalan P, et al. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial. JAMA. 2021; 326(18):1807-17. doi.10.1001/jama.2021.18295 PMid:34673895 PMCid:PMC8532039 6. Maskin LP, Bonelli I, Olarte GL, Palizas Jr F, Velo AE, Lurbet MF, et al. High-versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomized open-label clinical trial. J Intensive Care Med. 2022; 37(4):491-9. doi.10.1177/08850666211066799 PMid:34898320 PMCid:PMC8926919 7. Abani O, Abbas A, Abbas F, Abbas J, Abbas K, Abbas M, et al. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2023; 401(10387):1499-507. doi.10.1016/S0140-6736(23)00510-X PMid:37060915 8. Toroghi N, Abbasian L, Nourian A, Davoudi-Monfared E, Khalili H, Hasannezhad M, et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacol Rep. 2022; 74(1):229-40. doi.10.1007/s43440-021-00341-0 PMid:34837648 PMCid:PMC8627167 9. Wu H, Daouk S, Kebbe J, Chaudry F, Harper J, Brown B. Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. PLoS One. 2022; 17(10):e0275217. doi.10.1371/journal.pone.0275217 PMid:36190994 PMCid:PMC9529091 10. Modig K, Lambe M, Ahlbom A, Ebeling M. Excess mortality for men and women above age 70 according to level of care during the first wave of COVID-19 pandemic in Sweden: a population-based study. Lancet Reg Health Eur. 2021; 4: 100072. doi.10.1016/j.lanepe.2021.100072 PMid:34557812 PMCid:PMC8454796 11. Bencivenga L, Rengo G, Varricchi G. Elderly at time of CoronaVirus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition. Geroscience. 2020;42(4):1089-92. doi.10.1007/s11357-020-00218-9 PMid:32578073 PMCid:PMC7308600 12. Peterfi A, Meszaros A, Szarvas Z, Penzes M, Fekete M, Feher A, et al. Comorbidities and increased mortality of COVID-19 among the elderly: A systematic review. Physiol Int. 2023; 109(4):441-54. doi.10.1556/2060.2022.00206 PMid:35575986 13. Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E. SARS-CoV-2, COVID-19 and the aging immune system. Nat Aging. 2021; 1(9):769-82. doi.10.1038/s43587-021-00114-7 PMid:34746804 PMCid:PMC8570568 14. Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z, et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY). 2020; 12(13): 12493-503. doi.10.18632/aging.103579 PMid:32658868 PMCid:PMC7377860 15. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012; 380(9836): 37-43. doi.10.1016/S0140-6736(12)60240-2 PMid:22579043 16. Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience. 2020; 42(2):505-14. doi.10.1007/s11357-020-00186-0 PMid:32274617 PMCid:PMC7145538 17. Sabetsarvestani P, Rahnavard S, Hatami M, Bijani M, Nikrooz L. Investigating the Demographic Characteristics, Clinical Signs, Radiological and Laboratory Findings in Pregnant Women with COVID-19: A Cross-Sectional Study in Southern Iran. Avicenna J Nurs Midwifery Care. 2021; 29(3):256-63. doi.10.30699/ajnmc.29.3.256 18. Coelho L, Falcao F, Póvoa P, Viegas E, Martins AP, Carmo E, et al. Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients. Sci Rep. 2023; 13(1):4482. doi.10.1038/s41598-023-31544-5 PMid:36934143 PMCid:PMC10024012 19. Mehraeen E, SeyedAlinaghi S, Saeidi S, Heydari M. Identifying the self-care instructions for Patients with coronavirus not requiring hospitalization during the COVID-19 pandemic. RJMS. 2021; 27(11):72-82. 20. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of dexamethasone in hospitalized patients with COVID-19-preliminary report. medRxiv. 2020:2020.06.22.20137273. doi.10.1101/2020.06.22.20137273 21. Ho KS, Narasimhan B, Difabrizio L, Rogers L, Bose S, Li L, et al. Impact of corticosteroids in hospitalised COVID-19 patients. BMJ Open Respir Res. 2021; 8(1):e000766. doi.10.1136/bmjresp-2020-000766 PMid:33811098 PMCid:PMC8023732 22. Reyes LF, Rodriguez A, Bastidas A, Parra-Tanoux D, Fuentes YV, García-Gallo E, et al. Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19. J Crit Care. 2022;69:154014. doi.10.1016/j.jcrc.2022.154014 PMid:35217370 PMCid:PMC8863516 23. Li YM, Meng Q, Rao X, Wang B, Zhang X, Dong F, et al. Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study. Crit Care. 2020; 24(1):698. doi.10.1186/s13054-020-03429-w PMid:33339536 PMCid:PMC7747001
|
_-_Copy.png)
.png){kind=logo}
